Table 1.
ELISpot | CD8+ T cell IFN-γ | CD8+ T cell IFN-γ EM | Antibody |
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Vaccine | Status | Vol. | CSP | AMA1 | CSP | AMA1 | CSP | AMA1 | CSP | AMA1 |
DNA-Ad | P | v06 | 0 | +1.2 | 0 | 0 | 0 | 0 | −1.8 | −1.3 |
v10 | 0 | −2.01 | 0 | −4.2 | 0 | −11.51 | −2.3 | −1.4 | ||
v11 | −3.21 | −2.61 | −9.91 | −4.51 | −28.91 | −5.21 | −4.0 | −4.4 | ||
v18 | −1.61 | −1.81 | −2.41 | −2.51 | −2.41 | −3.01 | −1.4 | −2.1 | ||
Non-P | v01 | +4.9* | +1.8 | 0 | +1.4 | 0 | 0 | −1.7 | +1.1 | |
v02 | 0 | +3.0 | 0 | 0 | 0 | 0 | −1.2 | +2.3 | ||
v03 | +1.6 | +2.5 | −3.5 | −2.5 | 0 | 0 | −2.2 | +1.6 | ||
v05 | 0 | +3.3 | 1.0* | +1.1 | 0 | 0 | +2.7 | +2.5 | ||
v09 | 0 | +4.8* | +2.2* | 1.0 | 0 | 0 | +1.4 | +2.0 | ||
v12 | +1.8 | +1.2 | +1.1* | 1.0 | 0 | 0 | 1.0 | −2.8 | ||
v13 | 0 | +1.4 | 0 | 0 | 0 | 0 | 1.0 | +4.2 | ||
v15 | 0 | +2.8 | −4.4 | −1.2 | 0 | 0 | 1.0 | +1.1 | ||
v16 | 0 | +4.7 | 0 | −3.3 | 0 | 0 | 1.0 | +3.0 | ||
v17 | +1.1* | +2.0 | +1.45* | −4.0 | 0 | 0 | +6.7 | +3.7 | ||
v19 | 0 | +5.7* | −2.2 | −4.2 | 0 | 0 | −3.6 | 1.0 | ||
Ad-CA | Non-P | v118 | −2.1 | −1.4 | NT | NT | NT | NT | +4.6 | +133.3 |
v119 | −2.1 | −3.8 | −1.1 | −1.7 | −1.2 | −1.7 | +3.9 | +2.0 | ||
v125 | −1.7 | −1.6 | 1.0 | −2.1 | 0 | −1.9 | −1.5 | +7.1 | ||
v126 | −2.4 | −1.4 | −8.5 | −2.2 | 0 | −1.5 | +8.5 | +74.5 | ||
v127 | −1.9 | −2.4 | −1.2 | −3.2 | −1.2 | −3.2 | −1.7 | +7.3 | ||
v128 | −4.1 | −1.9 | +1.4 | +1.3 | NT | +1.4 | −1.7 | +10.0 | ||
v147 | −1.3 | −1.2 | −2.7 | +1.3 | −2.1 | 0 | 1.0 | +146.0 | ||
v149 | −1.1 | −1.2 | NT | NT | NT | NT | +5.8 | +9.7 | ||
v156 | −2.5 | −2.1 | −1.2 | −2.4 | −1.6 | −1.0 | +1.5 | +9.2 | ||
v160 | −1.5 | −1.3 | −3.6 | −3.2 | −6.5 | −23.8 | +1.8 | +2.1 | ||
v172 | −2.0 | −1.6 | −1.1 | −2.7 | 0 | −24.9 | +1.1 | +7.7 | ||
v173 | 1.0 | −1.3 | 0 | −1.2 | 0 | 0 | 0 | +15.3 | ||
v179 | −2.4 | −1.1 | −2.1 | −1.9 | 0 | −1.4 | −1.4 | +28.2 | ||
v184 | −4.9 | −3.1 | −1.7 | −1.1 | 0 | 0 | 0 | +475.0 | ||
v194 | −3.5 | −1.9 | 0 | −1.2 | 0 | 0 | −2.4 | +5.1 | ||
v195 | 0 | −4.2 | 1.0* | −1.5 | 0 | −1.2* | −1.4 | +10.1 | ||
v196 | −2.9 | −1.8 | −1.2 | −2.6 | 0 | −2.4 | +2.0 | +16.2 |
The effects of CHMI on pre-CHMI cellular and antibody activities are shown for each volunteer in the DNA/Ad and AdCA trials. The fold-change of pre- and post-CHMI activities is shown as a rise (+) or fall (−). The threshold for significance was fold-changes >±1.5, which was the range of changes in non-immunized infectivity controls: rises are shown in blue boxes, and falls are shown in green boxes.
Fold-changes of responses to immunodominant peptide pools.
Activity was negative pre-CHMI but was positive post-CHMI. 0: Pre-CHMI and post-CHMI activities were negative.